SAMHSA Aligned · Reviewed 2026-05-12 · MHPAEA Parity Verified

Medicare MAT Coverage: Suboxone, Methadone, Vivitrol Under Parts B and D

Coverage details, prior authorization, copays, network rules, appeal rights, and ASAM Level coverage for Medicare plans seeking Medication-Assisted Treatment (MAT).

(239) 496-8492 Free helpline · 24/7 confidential
Quick Verdict · ~30 sec read
Reviewed by RehabHive Editorial Team · Last updated 2026-05-12
Medicare covers all three FDA-approved MAT medications across Parts A, B, and D. Methadone is covered under Medicare Part B exclusively at SAMHSA-certified Opioid Treatment Programs (OTPs) since the 2020 SUPPORT Act expansion. Buprenorphine (Suboxone, Sublocade) is covered under Medicare Part D prescription drug plans at the public function index()– copay tier for generic forms in 2026. Vivitrol (extended-release naltrexone) is covered under Medicare Part B as a provider-administered injection. Most Medicare Advantage plans waive prior authorization on generic outpatient MAT. Original Medicare beneficiaries also need standalone Part D coverage for prescription buprenorphine.
SAMHSA & NIDA sourced ASAM Criteria 4ed View 6 sources

ASAM Levels Covered

Medicare aligns its coverage with the American Society of Addiction Medicine (ASAM) Criteria, the national standard for matching patients to the appropriate intensity of care.

ASAM Level Covered Coverage Notes
1.0 Outpatient Yes Office-based buprenorphine (Part D); Vivitrol (Part B); OTP methadone (Part B)
2.1 Intensive Outpatient Yes Medicare Part B IOP benefit since 2024; 9+ hrs/week, prior auth on MA plans
2.5 Partial Hospitalization Yes Medicare Part B PHP benefit; 20+ hrs/week with MAT continuation
3.1 Low-Intensity Residential Limited Original Medicare does not cover residential SUD; some Medicare Advantage plans add supplemental coverage
3.5 Medium-Intensity Residential Limited Original Medicare does not cover; select MA plans cover with prior auth
3.7 Medically Monitored Withdrawal Yes Medicare Part A inpatient hospital benefit when admitted to acute hospital for detox
4.0 Medically Managed Inpatient (Hospital) Yes Medicare Part A inpatient hospital benefit for complex withdrawal or co-occurring medical

Prior Authorization

Medicare prior authorization for MAT varies by Part and plan type. Methadone at OTPs under Part B has no prior authorization — Medicare reimburses the OTP the weekly bundled rate (HCPCS H0020) automatically when patient is enrolled in OUD treatment. Buprenorphine under Part D follows your specific Medicare Part D plan’s formulary: generic sublingual buprenorphine-naloxone is on most preferred tiers with no prior auth at FDA-labeled outpatient doses; brand Sublocade extended-release injection typically requires prior auth. Vivitrol under Part B requires prior auth as provider-administered medication, with most Medicare Advantage plans requiring documentation. Original Medicare has no prior auth on standard outpatient MAT, but Medicare Advantage plans may impose plan-level prior auth. Initial prior auth turnaround: 72 hours non-urgent, 24 hours urgent under federal rules.

Cost-Sharing

Medicare MAT cost-share varies by Part and plan. Methadone at OTPs under Original Medicare Part B: after 0 annual Part B deductible (2026), member pays 20% coinsurance on weekly bundled rate (-/week typical) unless Medigap supplement covers; Medigap Plan G covers all Part B coinsurance. Buprenorphine under Part D: 2026 brings public function index() copay on generic sublingual buprenorphine for many low-income subsidy (LIS) beneficiaries; non-LIS members typically public function index()- on most Part D plans’ preferred tier. Brand Sublocade - on Part D after step-therapy. Vivitrol under Part B: 20% coinsurance after deductible unless Medigap covers; Medicare Advantage typically public function index()- copay per injection. Medicare Advantage MAT often more comprehensive than Original Medicare due to plan-level supplemental benefits.

In-Network vs Out-of-Network

Original Medicare allows any Medicare-accepting OTP for methadone, any DEA-registered prescriber for buprenorphine, and any Medicare-accepting provider for Vivitrol administration. Medicare Advantage plans use their own networks — HMO MA plans require in-network except emergencies; PPO MA plans allow out-of-network at reduced coverage. For OTP methadone under MA, confirm the specific OTP holds a current MA contract. Medicare 2024 expansion increased OTP network nationally; SAMHSA Treatment Locator (1-800-662-4357) finds Medicare-accepting OTPs.

Step-Therapy & Fail-First

Original Medicare applies no step-therapy on MAT. Medicare Advantage plans may apply step-therapy on Part B drugs (Vivitrol) and Part D drugs (Sublocade, brand Suboxone) under CMS-approved Step Therapy Program rules, but only for new starts (not existing prescriptions) and with required exception process. Step-therapy exceptions: request with medical necessity documentation; MA plans must respond within 72 hours non-urgent / 24 hours urgent. CMS 2026 rules limit MA step-therapy on opioid use disorder medications.

Federal Parity (MHPAEA) Protections

MHPAEA does not directly apply to Original Medicare (Title XVIII federal program), but does apply to Medicare Advantage plans under separate CMS parity rules. MA plans cannot impose more restrictive financial requirements or NQTLs on SUD benefits than on comparable medical-surgical benefits, comparable to commercial MHPAEA. The 2024 CMS MA Final Rule strengthened parity enforcement on MA plans. For Original Medicare, ACA-related parity protections are limited but CMS coverage rules apply uniformly. File MA parity complaints with CMS at 1-800-MEDICARE.

Real-World Example

A 67-year-old Original Medicare beneficiary with Medigap Plan G in Florida started MAT for OUD in 2025. OTP weekly methadone billed Part B: /week × 52 weeks = public function index(),820 total Part B charges; Medigap Plan G covers all Part B coinsurance; member pays public function index() weekly. Generic buprenorphine through standalone Part D plan: public function index() copay (low-income subsidy qualified). Vivitrol monthly injection: declined in favor of methadone after OTP induction. Total annual MAT out-of-pocket: public function index() (Medigap covers all Part B; LIS covers all Part D). Original Medicare paid OTP /week, less than commercial; OTP volunteered the patient was stable on 80mg daily methadone with no adverse events at year-end.

Composite example for educational purposes; not a guarantee of coverage. Verify your specific plan benefits.

Frequently Asked Questions

Does Medicare cover Suboxone?
Yes. Buprenorphine-naloxone (Suboxone) is covered under Medicare Part D prescription drug plans. Generic sublingual buprenorphine-naloxone is on most Part D plans’ preferred tier at public function index()- copay in 2026 under the CMS opioid use disorder benefit. Brand Suboxone film and Sublocade extended-release injection typically require prior auth. Original Medicare beneficiaries need standalone Part D coverage for prescription buprenorphine.
Does Medicare cover methadone treatment?
Yes, since the 2020 SUPPORT Act expansion. Medicare Part B covers methadone for OUD exclusively at SAMHSA-certified Opioid Treatment Programs (OTPs). OTPs bill HCPCS H0020 weekly bundled rate covering medication, dispensing, drug testing, and counseling. After 0 annual Part B deductible (2026), member pays 20% coinsurance unless Medigap covers. Original Medicare has no prior auth requirement on OTP methadone.
Does Medicare cover Vivitrol?
Yes. Vivitrol (extended-release naltrexone, J-code J2315) is covered under Medicare Part B as a provider-administered injection. After 0 annual Part B deductible (2026), member pays 20% coinsurance unless Medigap covers all coinsurance. Medicare Advantage plans typically public function index()- copay per monthly injection. Most Medicare plans require prior auth on Vivitrol with documentation of OUD diagnosis and 7-10 days opioid-free.
Do I need a Medigap plan for MAT coverage?
Not strictly required, but Medigap (Medicare Supplement) significantly reduces out-of-pocket MAT cost. Without Medigap, Original Medicare beneficiaries pay 20% Part B coinsurance on methadone OTP services and Vivitrol injections after the annual Part B deductible. Medigap Plan G covers all Part B coinsurance — eliminating MAT out-of-pocket for Part B services. Medigap does not cover Part D prescription buprenorphine; separate Part D plan needed.
Does Medicare Advantage cover MAT differently than Original Medicare?
Medicare Advantage (MA) plans must cover everything Original Medicare covers, plus often add supplemental benefits. MA plans typically have lower copays on generic MAT (often public function index() vs Original Medicare 20%), Vivitrol ( public function index()- copay vs 20%), and integrated Part D coverage. Trade-off: MA plans use networks (HMO requires in-network) while Original Medicare uses any Medicare-accepting provider. Compare specific plans at medicare.gov.
Does Medicare cover MAT during inpatient hospital stay?
Yes. Medicare Part A inpatient hospital benefit covers MAT (buprenorphine, methadone, naltrexone) when administered during a covered inpatient hospital stay for medical reasons (e.g., admission for surgery, MAT continuation managed by hospital pharmacy). Medicare Part A does not cover standalone residential SUD treatment — residential is generally not Part A covered.
Does Medicare cover IOP and PHP for MAT?
Yes. Medicare Part B covers Intensive Outpatient Programs (IOP, since 2024 expansion under SUPPORT Act 2.0) and Partial Hospitalization Programs (PHP) when the patient has been hospitalized or is acutely at risk. MAT can be continued during IOP/PHP. Member pays 20% Part B coinsurance unless Medigap covers. Medicare Advantage plans typically lower copay.
Are appeals available for Medicare MAT denials?
Yes. Medicare appeals process: (1) Redetermination by Medicare contractor within 60 days; (2) Reconsideration by Qualified Independent Contractor within 60 days; (3) Administrative Law Judge hearing within 60 days; (4) Medicare Appeals Council; (5) Federal District Court. For Part D denials, appeal through your specific Part D plan’s grievance process. For Medicare Advantage, appeal through the MA plan’s process. Detailed instructions in your Medicare denial letter.
How do I find a Medicare-accepting OTP?
Use the SAMHSA Treatment Locator (findtreatment.gov or 1-800-662-4357) and filter for "Medicare accepted." All SAMHSA-certified OTPs are eligible to bill Medicare under the 2020 SUPPORT Act expansion, but each OTP must enroll in Medicare to bill. Most OTPs do enroll. Call ahead to confirm Medicare enrollment and any specific Medicare Advantage plan contracts.
Does Medicare cover MAT if I am under 65?
Yes for Medicare-eligible individuals under 65: those with disability (Social Security Disability Insurance), end-stage renal disease, or ALS qualify for Medicare regardless of age. Coverage rules are identical to age-65+ beneficiaries. SSDI beneficiaries with OUD often qualify for low-income subsidy (LIS) reducing Part D copays to public function index() on generic buprenorphine.

Sources & Citations

  1. 1
    CMS Medicare Coverage of Opioid Use Disorder Treatment Services — CMS guidance
  2. 2
    SUPPORT Act 2020 Medicare OUD Provisions — Federal legislation
  3. 3
    Medicare.gov Mental Health Care Coverage — CMS resource
  4. 4
    SAMHSA TIP 63: Medications for Opioid Use Disorder — Federal clinical guideline
  5. 5
    CMS Medicare Advantage Final Rule 2024 — CMS regulation
  6. 6
    NIDA Medications to Treat Opioid Addiction — NIH research summary
Free helpline · 24/7

Verify Your Medicare Coverage

Call the SAMHSA National Helpline 24/7 (free, confidential) or use our directory to find Medicare-network facilities offering Medication-Assisted Treatment (MAT).

SAMHSA 1-800-662-4357 All Medicare details →
Related Coverage

Compare Medicare with other coverage options

Medicare + Inpatient Residential Rehab
Coverage details, prior auth, copays
Medicare + Medical Detox
Coverage details, prior auth, copays
Medicare + Partial Hospitalization (PHP)
Coverage details, prior auth, copays
Medicare + Intensive Outpatient (IOP)
Coverage details, prior auth, copays
Medicare + Standard Outpatient
Coverage details, prior auth, copays
Aetna + Medication-Assisted Treatment (MAT)
Coverage details, prior auth, copays
BCBS + Medication-Assisted Treatment (MAT)
Coverage details, prior auth, copays
Cigna + Medication-Assisted Treatment (MAT)
Coverage details, prior auth, copays
UnitedHealthcare + Medication-Assisted Treatment (MAT)
Coverage details, prior auth, copays

Last reviewed: 2026-05-12 · RehabHive Editorial Team · Based on publicly available Medicare coverage policies, SAMHSA guidelines, and federal MHPAEA regulations.

This information is educational and does not constitute insurance advice. Verify your specific plan benefits directly with Medicare before making treatment decisions.